Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients

Halbsguth TV, Böll B, Borchmann P, Diehl V (2011) The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep 6:164–171

Proctor SJ, Wilkinson J, Sieniawski M (2009) Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 71:222–232

Evens AM, Sweetenham J.W, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park, NY) 2008;22:369–379

Klimm B, Diehl V, Engert A. Hodgkin’s lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park, NY) 2007;21:982–990

Prochazka V, Gawande RS, Cayci Z et al (2018) Positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 24:64–70

Moskowitz AJ, Schoder H, Gavane S et al (2017) Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 130:2196–2203

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A, Cheson BD (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32:3048–3058

Kostakoglu L, Chauvie S (2018) Metabolic tumour volume metrics in lymphoma. Semin Nucl Med 48:50–66

Albano D, Bosio G, Pagani C, Re A, Tucci A, Giubbini R, Bertagna F (2019) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging 46:87–96

Albano D, Bertoli M, Battistotti M, Rodella C, Statuto M, Giubbini R, Bertagna F (2018) Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma. Ann Nucl Med 32:532–541

Albano D, Bosio G, Bianchetti N et al (2019) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. Ann Nucl Med 33:280–287

Albano D, Bosio G, Camoni L, Farina M, Re A, Tucci A, Giubbini R, Bertagna F (2019) Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma. Hematol Oncol 37:39–46

Procházka V, Klugar M, Bachanova V et al (2016) Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy. BMJ Open 5:6

Boellaard R, Delgado-Bolton R, Oyen WJ et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354

Bentur OS, Dann EJ, Paran E, Lavie D, Nachmias B, Ron Y et al (2019) Interim PET-CT-guided therapy in elderly patients with Hodgkin lymphoma-a restroispective national multi-center study. Ann Hematol. https://doi.org/10.1007/s00277-019-03686-y

Thyss A, Saada E, Gastaud L, Peyrade F, Ré D (2014) Hodgkin's lymphoma in older patients: an orphan disease? Mediterr J Hematol Infect Dis 6:e2014050

Jagadeesh D, Diefenbach C, Evens AM (2013) XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. Hematol Oncol 69(Suppl 1):–75

Björkholm M, Weibull CE, Eloranta S, Smedby KE, Glimelius I, Dickman PW (2018) Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-a population-based study from Sweden. Eur J Haematol 101:106–114

Ballova V, Ruffer JU, Haverkamp H et al (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16:124–131

Evens AM, Hong F (2013) How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol 31:1502–1505

Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P (2013) ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 31:1522–1529

Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161:76–86

Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F, Intergruppo Italiano Linfomi (IIL) Intergruppo Italiano Linfomi (IIL) (2004) VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 15:123–128

Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJQ, James PW, Goodlad JR (2012) Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 119:6005–6015

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, la Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A, on behalf of the PETAL Trial Investigators (2018) Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol 36:2024–2034

Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, Toubeau M, Ferrant E, Brunotte F, Casasnovas RO (2014) Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41:1735–1743

Rogasch JMM, Hundsdoerfer P, Hofheinz F, Wedel F, Schatka I, Amthauer H, Furth C (2018) Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin’s lymphoma. BMC Cancer 18:521

Eichenauer DA, Plütschow A, Fuchs M, Sasse S, Baues C, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A (2019) Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group. J Clin Oncol 38:698–705. https://doi.org/10.1200/JCO.19.00986

Andrè MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35:1786–1794

Barrington SF, Philipps EH, Counsell N et al (2019) Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID study. J Clin Oncol 37:1732–1741